CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TILT Biotherapeutics is developing TILT-123, an oncolytic immunotherapy for advanced solid tumors. The project aims to demonstrate the safety and efficacy of TILT-123 in combination with existing therapies for melanoma and other cancers, addressing a critical need for new treatment options.
TILT Biotherapeutics is developing a breakthrough oncolytic immunotherapy for treatment for cancer.
Advanced solid tumors are currently incurable and limited treatment options are available – preclinical data on TILT technology suggests curative potential.
There are over 9 million people dying from cancer each year and the incidence is growing rapidly.
New immunotherapies for cancer are more widely available in America than in Europe partly because clinical research concentration in the U.S.
Can…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
